Stock Events

Stock Events

OmniAb 

$2.42
23
+$0.03+1.26% Thursday 20:00
+$0.00+0%Thursday 20:01After hours

Statistics

Day High
2.43
Day Low
2.41
52W High
2.79
52W Low
1.3
Volume
10,385
Avg. Volume
-
Mkt Cap
350.83M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.17
-0.13
-0.1
-0.06
Expected EPS
-0.12
Actual EPS
N/A

Financials

-347.04%Profit Margin
Unprofitable
2021
2022
2023
2024
2025
18.67MRevenue
-64.78MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow OABI. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap66.35B
Regeneron Pharmaceuticals is a leading biotech company that competes with OmniAb in the development of monoclonal antibodies for various therapeutic areas.
AMGEN
AMGN
Mkt Cap193.39B
Amgen is a biopharmaceutical company that competes in the discovery, development, and manufacturing of human therapeutics, including monoclonal antibodies, similar to OmniAb's focus.
Lilly(Eli) &
LLY
Mkt Cap1.08T
Eli Lilly and Company is a competitor due to its strong focus on antibody therapies, including its efforts in immunology and oncology, areas that overlap with OmniAb's interests.
Gilead Sciences
GILD
Mkt Cap158.77B
Gilead Sciences competes with OmniAb in the biopharmaceutical field, particularly in the development of treatments that involve monoclonal antibodies for infectious diseases, among others.
Bristol-Myers Squibb
BMY
Mkt Cap117.46B
Bristol-Myers Squibb is involved in the discovery and development of innovative medicines, including monoclonal antibodies for cancer and other diseases, making it a competitor to OmniAb.
Merck
MRK
Mkt Cap317.77B
Merck & Co., Inc. competes with OmniAb through its extensive research and development in biopharmaceuticals, including therapies based on monoclonal antibodies for various diseases.
Pfizer
PFE
Mkt Cap138.44B
Pfizer is a global pharmaceutical company that competes with OmniAb in the development and commercialization of biopharmaceuticals, including monoclonal antibodies for a wide range of conditions.
Astrazeneca
AZN
Mkt Cap292.2B
AstraZeneca is a competitor because of its focus on the development of biopharmaceuticals, including monoclonal antibodies for the treatment of diseases in areas like oncology, which overlaps with OmniAb's focus.
Roche
RHHBY
Mkt Cap333.25B
Roche Holding AG competes with OmniAb through its subsidiary Genentech in the research and development of monoclonal antibody therapies, particularly in oncology and immunology.
Sanofi
SNY
Mkt Cap102.81B
Sanofi competes with OmniAb in the global healthcare market, particularly in the development of monoclonal antibodies for immunological diseases, an area of focus for OmniAb.

About

OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
Show more...
CEO
Mr. Matthew W. Foehr
Employees
114
Country
United States
ISIN
US68218J1034

Listings

BOATS
BOATS
OABI.BOATS
XNAS
US
OABI
XNAS
US
OABIW

0 Comments

Share your thoughts

FAQ

What is OmniAb stock price today?▼
The current price of OABI is $2.42 USD — it has increased by +1.26% in the past 24 hours. Watch OmniAb stock price performance more closely on the chart.
What is OmniAb stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange OmniAb stocks are traded under the ticker OABI.
Is OmniAb stock price growing?▼
OABI stock has fallen by -3.97% compared to the previous week, the month change is a -2.42% fall, over the last year OmniAb has showed a +23.51% increase.
What is OmniAb market cap?▼
Today OmniAb has the market capitalization of 350.83M
When is the next OmniAb earnings date?▼
OmniAb is going to release the next earnings report on August 06, 2026.
What were OmniAb earnings last quarter?▼
OABI earnings for the last quarter are -0.06 USD per share, whereas the estimation was -0.1 USD resulting in a +42.47% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is OmniAb revenue for the last year?▼
OmniAb revenue for the last year amounts to 18.67M USD.
What is OmniAb net income for the last year?▼
OABI net income for the last year is -64.78M USD.
How many employees does OmniAb have?▼
As of July 05, 2026, the company has 114 employees.
In which sector is OmniAb located?▼
OmniAb operates in the Health & Wellness sector.
When did OmniAb complete a stock split?▼
OmniAb has not had any recent stock splits.
Where is OmniAb headquartered?▼
OmniAb is headquartered in EmeryVille, United States.